Although these individuals have been described for decades, they have received increasing attention over the past few years due to growing interest in characterizing the preclinical stages of Alzheimer’s disease (AD). Subjective cognitive decline (SCD) refers to individuals’ perceived decline in memory and/or other cognitive abilities relative to their previous level of performance, in the absence of objective neuropsychological deficits. Altogether, our findings highlight the relevance of assessing psychoaffective factors and informant-reported SCD in SCD populations and point to both differences and similarities in SCD populations referring or not to a memory clinic. Yet, both the SCD groups were quite similar otherwise including for brain amyloid load and the SCD-community showed increased depression score over time. The same group appears as a frailer population than SCD-community as they show greater atrophy progression over time. Higher subclinical depression and informant-reported SCD specifically characterize the SCD group that refers to a memory clinic.
Higher self-reported SCD correlated with (i) lower grey matter volume and higher anxiety in SCD-community, (ii) greater informant-reported SCD in SCD-clinic, and (iii) lower glucose metabolism in both SCD groups. A significant increase over time was found for depression in the SCD-community and for self-reported praxis-domestic activities SCD factor in the SCD-clinic. Compared to SCD-community, SCD-clinic showed higher informant-reported SCD, depression score, and atrophy progression over time but similar brain amyloid load. ResultsĬompared to HC, both SCD groups showed similar cognitive performances but higher informant-reported SCD and anxiety. We also investigated SCD substrates within each SCD group through the correlations between self-reported SCD and other psychometric and brain measures. The groups were compared in terms of baseline and follow-up levels of SCD (self- and informant-reported), cognition, subclinical anxiety and depression, and atrophy progression over time. They were followed up over a mean period of 2.4 ± 0.8 years. Participants underwent cognitive, psychoaffective, structural MRI, FDG-PET, and amyloid-PET assessments. Seventy-eight cognitively unimpaired older adults from the IMAP+ study (Caen) were included, amongst which 28 healthy controls (HC) and 50 SCD recruited from the community (SCD-community n = 23) or from a memory clinic (SCD-clinic n = 27). We aimed at characterizing SCD populations according to whether or not they referred to a memory clinic, by assessing the factors associated with increased AD risk. Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer’s disease (AD).
0 kommentar(er)
